Related Experiment Videos
Reversible ophthalmoplegia in CPEO
1Sydney Eye Hospital, Woolloomooloo, NSW.
Australian and New Zealand Journal of Ophthalmology
|August 1, 1995
Summary
Coenzyme Q10 supplementation improved ocular motility in a patient with chronic progressive external ophthalmoplegia (CPEO). This finding suggests CoQ10 may help limit ophthalmoplegia progression.
Area of Science:
- Neurology
- Ophthalmology
- Biochemistry
Background:
- Chronic progressive external ophthalmoplegia (CPEO) is a debilitating neuromuscular disorder affecting eye movements.
- Mitochondrial dysfunction is implicated in the pathogenesis of CPEO.
- Coenzyme Q10 (CoQ10) is a vital component of the mitochondrial electron transport chain.
Observation:
- A single patient diagnosed with CPEO was treated with Coenzyme Q10.
- The treatment involved daily supplementation of 300 mg CoQ10 for three years.
- A brief trial of 200 mg daily was conducted after one year.
Findings:
- Significant improvement in ocular motility was observed during CoQ10 treatment.
- Ocular ductions, measured by synoptophore, demonstrated enhancement.
- The positive effects on eye movements were sustained throughout the treatment period.
Implications:
- Coenzyme Q10 may be a beneficial therapeutic agent for managing CPEO.
- This case highlights the potential role of CoQ10 in mitigating mitochondrial-related ophthalmoplegia.
- Further research into CoQ10's efficacy in larger CPEO cohorts is warranted.